Peloton Wealth Strategists’s Neurocrine Biosciences NBIX Stock Holding History

Peloton Wealth Strategists’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.44M	Buy	14,485 +1,150	+9%	+$171K	0.9%	42
2026 Q1	$1.76M	Sell	13,335 -225	-2%	-$29.9K	0.71%	52
2025 Q4	$1.92M	Sell	13,560 -250	-2%	-$36.2K	0.75%	50
2025 Q3	$1.94M	Sell	13,810 -1,100	-7%	-$149K	0.76%	48
2025 Q2	$1.87M	Sell	14,910 -80	-0.5%	-$9.17K	0.75%	49
2025 Q1	$1.66M	Buy	14,990 +875	+6%	+$111K	0.69%	53
2024 Q4	$1.93M	Buy	14,115 +10,600	+302%	+$1.31M	0.78%	45
2024 Q3	$405K	Buy	+3,515	New	+$482K	0.16%	82

Other funds holding NBIX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Peloton Wealth Strategists's NBIX Position: Q2 2026 in Review

Peloton Wealth Strategists increased its Neurocrine Biosciences (NBIX) stake by 8.6% in Q2 2026, buying an estimated $171K and bringing the position to 14,485 shares worth $2.44M. The position accounts for 0.9% of the portfolio, ranked #42.

Peloton Wealth Strategists first reported a position in NBIX in Q3 2024 and has held it in 8 quarters since. 780 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

Peloton Wealth Strategists held 14,485 shares of Neurocrine Biosciences worth $2.44M as of Q2 2026.
Peloton Wealth Strategists bought 1,150 Neurocrine Biosciences shares in Q2 2026, an estimated $171K.
Neurocrine Biosciences made up 0.9% of Peloton Wealth Strategists's portfolio in Q2 2026, its #42 holding.
Peloton Wealth Strategists first reported a position in Neurocrine Biosciences in Q3 2024 and has held it in 8 quarters since.
780 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on Peloton Wealth Strategists's 13F filing for Q2 2026, filed 10 Aug 2026.